Surufatinib DDI With a PPI and a CYP3A Inducer

Inclusion Criteria * Non-smoking, healthy male or female between the ages of 18 and 55 years (inclusive) * Body mass index (BMI) \> 18 and ≤ 29 kg/m2 * Females must be of non-childbearing potential or surgically sterile * Males who have not had a successful vasectomy and are partners of women of childbearing potential must use, or their partners must use, a medically acceptable method of contraception starting for at least 1 menstrual cycle prior to and throughout the entire study period, and for 2 weeks after the last dose of study drug. Those with partners using hormonal contraceptives must also use an additional approved method of contraception such as a condom with spermicide. Males who have had a successful vasectomy (confirmed azoospermia, documentation needed) require no additional contraception. No sperm donation is allowed during the study period and for 90 days after study drug discontinuation. Exclusion Criteria * Evidence of clinically significant cardiovascular, hepatic, GI, renal, respiratory, endocrine, hematological, neurological, or psychiatric disease or abnormalities * Known history of any GI surgery or any condition possibly affecting drug absorption, however appendectomy and hernia repair will be allowed * Clinically significant illness within 8 weeks or a clinically significant infection within 4 weeks prior to first dose * Known food allergy deemed clinically significant. * Clinically significant deviation from normal in the physical examination, vit…